Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database
Peter C. Taylor, Tsutomu Takeuchi, Gerd R Burmester, Patrick Durez, Josef S Smolen, Walter Deberdt, Maher Issa, Jorge Ross Terrés, Natalia Bello, Kevin Winthrop
Topics & Concepts
MedicineRheumatoid arthritisJanus kinase inhibitorTerm (time)Internal medicineExtension (predicate logic)SurgeryDermatologyTofacitinibProgramming languageQuantum mechanicsPhysicsComputer scienceRheumatoid Arthritis Research and TherapiesSpondyloarthritis Studies and TreatmentsHER2/EGFR in Cancer Research